Search Within

Colleen Anne Maher

Formats
  1. Journal Article (9)
  2. Meeting Abstract (7)
Groups
  1. Department of Medicine (16)
  2. Solid Tumor Oncology Division (16)
  3. Melanoma and Immunotherapeutics Service (15)
  4. Weinberg Fellows (12)
  5. Biostatistics Service (10)
  6. Epidemiology and Biostatistics (10)

More Groups

People
  1. Margaret Callahan (12)
  2. Katherine Panageas (9)
  3. Jedd Wolchok (8)
  4. Michael Postow (8)
  5. Jonathan Rosenberg (7)
  6. Samuel Funt (7)

More People

Years
  1. 2025 (2)
  2. 2024 (3)
  3. 2023 (3)
  4. 2022 (3)
  5. 2021 (2)
  6. 2020 (1)

More Years

Publications
  1. Journal of Clinical Oncology (6)
  2. Annals of Oncology (1)
  3. Cell Reports (1)
  4. Cell Reports Methods (1)
  5. Clinical Cancer Research (1)
  6. Journal for ImmunoTherapy of Cancer (1)

More Publications

Publishers
  1. American Society of Clinical Oncology (6)
  2. Cell Press (2)
  3. Nature Publishing Group (2)
  4. American Association for Cancer Research (1)
  5. American Association for the Advancement of Science (1)
  6. Biomed Central Ltd (1)

More Publishers

Results (16)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Neoantigen-specific CD8 T cell responses in the peripheral blood following PD-L1 blockade might predict therapy outcome in metastatic urothelial carcinoma
    Journal Article

    Holm, J. S.; Funt, S. A.; Borch, A.; Munk, K. K.; Bjerregaard, A. M.; Reading, J. L.; Maher, C.; Regazzi, A.; Wong, P.; Al-Ahmadie, H.; more...
    Nature Communications (2022)

    Fulltext@MSK | Save
  • LAG-3 expression on peripheral blood cells identifies patients with poorer outcomes after immune checkpoint blockade
    Journal Article

    Shen, R.; Postow, M. A.; Adamow, M.; Arora, A.; Hannum, M.; Maher, C.; Wong, P.; Curran, M. A.; Hollmann, T. J.; Jia, L.; more...
    Science Translational Medicine (2021)

    Fulltext@MSK | Save
  • Checkpoint blockade in melanoma patients with underlying chronic lymphocytic leukemia
    Journal Article

    Smithy, J. W.; Pianko, M. J.; Maher, C.; Postow, M. A.; Shoushtari, A. N.; Momtaz, P.; Chapman, P. B.; Wolchok, J. D.; Park, J. H.; Callahan, M. K.
    Journal of Immunotherapy (2021)

    Fulltext@MSK | Save
  • Interrogation of neoantigen-specific CD8 T cells in peripheral blood following PD-L1 blockade in patients with metastatic urothelial carcinoma (mUC)
    Meeting Abstract

    Holm, J. S.; Funt, S. A.; Bjerregaard, A. M.; Reading, J. L.; Maher, C. A.; Regazzi, A. M.; Wong, P.; Al-Ahmadie, H.; Overgaard, N. H.; Tamhane, T.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Durable clinical benefit from combination ipilimumab (IPI) and nivolumab (NIVO) in anti-PD-1 therapy resistant, platinum resistant metastatic urothelial carcinoma (mUC)
    Meeting Abstract

    Keegan, N. M.; Funt, S. A.; Kania, B. E.; Iyer, G.; Clement, J. M.; McCoy, A. S.; Hettich, G.; Ziv, E.; Maher, C. A.; Nair, S.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Neurologic immune related adverse events (irAEs) in patients treated with immune checkpoint blockade
    Meeting Abstract

    Santomasso, B.; Haggiagi, A.; Malani, R.; Maher, C. A.; Holder, J. N.; Shames, Y.; Wilcox, J.; Flynn, J.; Briggs, S.; Panageas, K.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save